Ventures Inc.Vulcan Capital... Net Worth

The estimated Net Worth of Ventures Inc.Vulcan Capital... is at least $25.9 Million dollars as of 25 June 2013. Ventures Capital owns over 333,333 units of PTC Therapeutics Inc stock worth over $25,914,972 and over the last 11 years Ventures sold PTCT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Capital PTCT stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the PTC Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ventures bought 333,333 units of PTCT stock worth $4,999,995 on 25 June 2013.

The largest trade Ventures's ever made was buying 333,333 units of PTC Therapeutics Inc stock on 25 June 2013 worth over $4,999,995. On average, Ventures trades about 333,333 units every 0 days since 2013. As of 25 June 2013 Ventures still owns at least 803,067 units of PTC Therapeutics Inc stock.

You can see the complete history of Ventures Capital stock trades at the bottom of the page.

Insiders trading at PTC Therapeutics Inc

Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel, and Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.

What does PTC Therapeutics Inc do?

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.

Complete history of Ventures Capital stock trades at PTC Therapeutics Inc

PTC Therapeutics Inc executives and stock owners

PTC Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stuart Peltz,
  Chief Executive Officer, Director
• Neil Almstead,
  Chief Technical Operations Officer
• Mark Boulding,
  Executive Vice President, Chief Legal Officer
• Emily Hill,
  Principal Financial Officer, Treasurer
• Dr. Stuart W. Peltz,
  Co-Founder, CEO & Exec. Director
• Christine Utter,
  Senior Vice President - Finance, Chief Accounting Officer
• Mark Elliott Boulding,
  Exec. VP & Chief Legal Officer
• Dr. Neil Almstead,
  Chief Technical Operations Officer
• Michael Schmertzler,
  Independent Chairman of the Board
• Allan Jacobson,
  Independent Director
• Emma Reeve,
  Independent Director
• David Southwell,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Glenn Steele,
  Independent Director
• Jerome Zeldis,
  Independent Director
• Stephanie Okey,
  Independent Director
• Dr. Allan Steven Jacobson,
  Independent Co-Founder, Chairman of Scientific Advisory Board & Director
• Eric Pauwels,
  Chief Business Officer
• Matthew Klein,
  Chief Development Officer
• Jane Baj,
  VP of Corp. Communications
• Alex Kane,
  Investor Relations Officer
• Ellen Welch Ph.D.,
  Chief Scientific Officer
• Christine Utter,
  Sr. VP, Chief Accounting Officer & Head of People Services
• Adam Koppel,
  Director
• Cameron Geoffrey Mc Donough,
  Director
• Tuyen Ong,
  Chief Medical Officer
• Marcio Souza,
  Chief Operating Officer
• Pharma Holdings Ii, Llc Com...,
  10% owner
• Mark Rothera,
  Chief Commercial Officer
• Ronald C Jr Renaud,
  Director
• Suisse/ Credit,
  
• Claudia De Oliveira Ribeiro...,
  President
• Bioventures Cayman Ltd Hbm,
  10% owner
• Robert J. Spiegel,
  Chief Medical Officer
• Richard Aldrich,
  Director
• Ventures Inc.Vulcan Capital...,
  
• Shane William Charles Kovacs,
  EVP, CFO & Head of Corp Dev
• Axel Bolte,
  Director
• Michael L Kranda,
  Director
• Pierre Gravier,
  CHIEF FINANCIAL OFFICER
• Mary L. Smith,
  
• William F. Jr. Bell,
  
• Alethia Young,
  
• Lee Scott Golden,
  EVP & CHIEF MEDICAL OFFICER